Taken together, the data suggest that (i) nanaomycin induces neuroblastoma cell death but results in Nrf2, BRD3 and BRD4 protein recruitment to the Nrf2 target gene promoters and increases promoter activity, leading to Nrf2 target gene up-regulation; (ii) JQ1 blocks nanaomycin-mediated Nrf2 target gene expression; and (iii) JQ1 exerts synergistic anticancer effects with nanaomycin by blocking Nrf2-antioxidant signaling pathway activation. This evidence concerns the gene BRD4 and neuroblastoma.